158.19
0.15%
+0.23
After Hours:
158.26
0.07
+0.04%
Overview
News
Price History
Option Chain
Why JNJ Down?
Discussions
Forecast
Stock Split
Dividend History
Johnson & Johnson stock is currently priced at $158.19, with a 24-hour trading volume of 6.05M.
It has seen a +0.15% increased in the last 24 hours and a -2.08% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $157.2 pivot point. If it approaches the $159.0 resistance level, significant changes may occur.
Johnson & Johnson Stock (JNJ) Financials Data
Johnson & Johnson (JNJ) Revenue 2023
JNJ reported a revenue (TTM) of $93.02 billion for the quarter ending December 31, 2023, a +6.46% rise year-over-year.
Johnson & Johnson (JNJ) Net Income 2023
JNJ net income (TTM) was $35.15 billion for the quarter ending December 31, 2023, a +95.94% increase year-over-year.
Johnson & Johnson (JNJ) Cash Flow 2023
JNJ recorded a free cash flow (TTM) of $17.78 billion for the quarter ending December 31, 2023, a +3.45% increase year-over-year.
Johnson & Johnson (JNJ) Earnings per Share 2023
JNJ earnings per share (TTM) was $12.11 for the quarter ending December 31, 2023, a +79.67% growth year-over-year.
Johnson & Johnson Stock (JNJ) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Broadhurst Vanessa | EVP, Global Corp Affairs |
Mar 13 '24 |
Sale |
162.16 |
8,891 |
1,441,765 |
15,043 |
JOHNSON & JOHNSON | 10% Owner |
Feb 29 '24 |
Option Exercise |
0.72 |
3,855 |
2,792 |
4,103,430 |
JOHNSON & JOHNSON | 10% Owner |
Feb 16 '24 |
Sale |
25.81 |
3,725 |
96,142 |
4,099,575 |
Decker Robert J | VP Corporate Controller |
Feb 13 '24 |
Option Exercise |
0.00 |
313 |
0 |
19,059 |
Broadhurst Vanessa | EVP, Global Corp Affairs |
Feb 13 '24 |
Option Exercise |
0.00 |
408 |
0 |
24,143 |
Forminard Elizabeth | Executive VP, General Counsel |
Feb 13 '24 |
Option Exercise |
0.00 |
651 |
0 |
8,576 |
Duato Joaquin | CEO and Chairman of the Board |
Feb 13 '24 |
Option Exercise |
0.00 |
3,470 |
0 |
364,809 |
Hait William | See Remarks |
Feb 13 '24 |
Option Exercise |
0.00 |
834 |
0 |
39,074 |
Fasolo Peter | Exec VP, Chief HR Officer |
Feb 13 '24 |
Option Exercise |
0.00 |
925 |
0 |
112,550 |
Schmid Timothy | EVP, WW Chair, MedTech |
Feb 13 '24 |
Option Exercise |
0.00 |
499 |
0 |
13,290 |
Johnson & Johnson Stock (JNJ) Latest News
Shockwave Medical (SWAV) Up on Potential Acquisition Rumors
Zacks Investment Research
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
Zacks Investment Research
4 Best ETF Areas of Q1
Zacks Investment Research
3 Dividend Stocks That Are Likely to Raise Their Payouts in April
The Motley Fool
Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst
Benzinga
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
Zacks Investment Research
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Cap:
|
Volume (24h):